Moreover, in BRCA1-mutated breast cancers, this sialyltransferase inhibitor was reported to neutralize acidic tumor-permissive microenvironment and sensitize cancer cells to immune checkpoint blockade by activating CD8+ T cells and inhibiting tumor growth and metastasis [50]. This evidence concerns the gene CD8A and breast cancer.